As part of the collaboration worth $300m, Boehringer and Epizyme will involve in the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed
The post Boehringer, Epizyme announce $300m oncology therapy program appeared first on Pharmaceutical Business review.
Original Article: Boehringer, Epizyme announce $300m oncology therapy program